Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy.
Roberts JA, Ulldemolins M, Liu X, Baptista JP, Bilgrami I, Boidin C, Brinkmann A, Castro P, Choi G, Cole L, De Waele JJ, Deans R, Donnellan S, Eastwood GM, Frey OR, Goutelle S, Gresham R, Jamal JA, Joynt GM, Kanji S, Kluge S, König C, Koulouras VP, Lassig-Smith M, Laterre PF, Lee A, Lefrant JY, Lei K, Leung P, Llaurado-Serra M, Martin-Loeches I, Nor MBM, Mudaliar Y, Ostermann M, Paul SK, Peake SL, Rello J, Roberts DM, Roberts MS, Richards B, Rodríguez A, Roehr AC, Roger C, Seoane L, Sinnollareddy M, Sousa E, Soy D, Spring A, Starr T, Stephens D, Taccone FS, Thomas J, Turnidge J, Valkonen M, Varghese JM, Wallis SC, Walker RJ, Williams T, Wilson LC, Wittebole X, Wright DFB, Zikou XT, Bellomo R, Lipman J; SMARRT Study Collaborators.
Roberts JA, et al.
Intensive Care Med. 2025 Sep;51(9):1628-1640. doi: 10.1007/s00134-025-08067-w. Epub 2025 Aug 13.
Intensive Care Med. 2025.
PMID: 40801954